PATENT COOPERATION TREATY

Translation

PCT

INTERNATIONAL PRELIMINARY REPORT ON PATENTABILITY (Chapter II of the Patent Cooperation Treaty)

(PCT Article 36 and Rule 70)

Applicant's or agent's file reference			
443449EH	FOR FURTHER ACTION	See Form PCT/IPEA/416	
International application No.	International filing date (day/month/year)	Priority date (day/month/year)	
PCT/EP2004/009536	26.08.2004	29.08.2003	
International Patent Classification (IPC) or national classification and IPC			
A61K7/48, A61K33/38			
Applicant BIO-GATE AG.			
 This report is the international preliminary examination report, established by this International Preliminary Examining Authority under Article 35 and transmitted to the applicant according to Article 36. 			
2. This REPORT consists of a total of sheets, including this cover sheet.			
3. This report is also accompanied by ANNEXES, comprising:			
a. (sent to the applicant and to the International Bureau) a total of sheets, as follows:			
sheets of the description, claims and/or drawings which have been amended and are the basis for this report and/or sheets containing rectifications authorized by this Authority (see Rule 70.16 and Section 607 of the Administrative Instructions).			
sheets which supersede earlier sheets, but which this Authority considers contain an amendment that goes beyond the disclosure in the international application as filed, as indicated in item 4 of Box No. I and the Supplemental Box.			
b. (sent to the International Bureau only) a total of (indicate type and number of electronic carrier(s))			
containing a regrupped listing and/outskless			
containing a sequence listing and/or tables related thereto, in computer readable form only, as indicated in the Supplemental Box Relating to Sequence Listing (see Section 802 of the Administrative Instructions).			
4. This report contains indications relating to the following items:			
Box No. I Basis of t	he report		
Box No. II Priority	Priority		
Box No. III Non-esta	Box No. III Non-establishment of opinion with regard to novelty, inventive step and industrial applicability		
Box No. IV Lack of u	V Lack of unity of invention		
	Box No. V Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability: citations and explanations supporting such statement		
Box No. VI Certain d	Certain documents cited		
Box No. VII Certain d	Certain defects in the international application		
Box No. VIII Certain observations on the international application			
Date of submission of the demand	Date of completion	of this report	
		. •	
Name and mailing address of the IPEA/EP	Authorized officer		
.			
Forginila No.	7.1		
Facsimile No.	Telephone No.		

INTERNATIONAL PRELIMINARY REPORT ON PATENTABILITY

International application No.

PCT/EP2004/009536 Box No. I Basis of the report With regard to the language, this report is based on the international application in the language in which it was filed, unless otherwise indicated under this item. This report is based on translations from the original language into the following language which is the language of a translation furnished for the purposes of: international search (Rule 12.3 and 23.1(b)) publication of the international application (Rule 12.4) international preliminary examination (Rule 55.2 and/or 55.3) With regard to the elements of the international application, this report is based on (replacement sheets which have been furnished to the receiving Office in response to an invitation under Article 14 are referred to in this report as "originally filed" and are not annexed to the international application as originally filed/furnished the description: as originally filed/furnished received by this Authority on pages^{sk} ______ received by this Authority on the claims: as originally filed/furnished nos.* ______ as amended (together with any statement) under Article 19 nos.* 1,15,16 09.06.2005 with letter of 07.06.2005 received by this Authority on the drawings: as originally filed/furnished 1/2,2/2 sheets received by this Authority on received by this Authority on a sequence listing and/or any related table(s) - see Supplemental Box Relating to Sequence Listing. The amendments have resulted in the cancellation of: the description. pages the claims, nos. the drawings, sheets/figs __ the sequence listing (specify): any table(s) related to sequence listing (specify): This report has been established as if (some of) the amendments annexed to this report and listed below had not been made, since they have been considered to go beyond the disclosure as filed, as indicated in the Supplemental Box (Rule 70.2(c)). the description, pages the claims, nos. the drawings, sheets/figs the sequence listing (specify): any table(s) related to sequence listing (specify): If item 4 applies, some or all of those sheets may be marked "superseded."

INTERNATIONAL PRELIMINARY REPORT ON PATENTABILITY

International application No.
PCT/EP2004/009536

	004/009536	
Box No. V Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability: citations and explanations supporting such statement		
1. Statement		
Novelty (N) Claims 1-31	YES	
Claims		
Inventive step (IS) Claims	VT.C	
Claims 1-31		
Industrial applicability (IA) Claims 1-31 Claims		
2. Citations and explanations (Rule 70.7)		
1. Reference is made to the following documents:		
D1: WO 02/17984 A (STEINRUECKE PETER; BECHER	Γ	
THORSTEN (DE); BIO GATE BIOINNOVATIVE MAT	IE),	
7 March 2002 (2002-03-07)		
D2: US-A-5 595 750 (JACOBSON HOWARD W ET AL),	,	
21 January 1997 (1997-01-21)		
D3: US-A-4 828 832 (DE CUELLAR BLANCA ROSA A	ET AL),	
9 May 1989 (1989-05-09)		
D4: US-A-4 906 466 (PRATT ALLIN S ET AL),		
6 March 1990 (1990-03-06)		
The amendments submitted with the letter of 7	June 2005	
do not introduce any material that violates the	he	
requirement of PCT Article 34(2)(b) by going 1	beyond the	
disclosure in the international application a	s filed.	
O Nove 34 (DOM 3 1-1- 22 (2))		
2. Novelty (PCT Article 33(2))		
2. Novelty (PCT Article 33(2))		
The subject matter of claims 1 to 31 is novel	(PCT	

Document D1 discloses an antimicrobial material

International application No.
PCT/EP2004/009536

Box No. V

Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability: citations and explanations supporting such statement

for implantation in bones, or for coating or manufacturing an implant or an implantable medical device, comprising finely dispersed particles of an antimicrobial metal in a material that forms a matrix in its cured state. According to the invention, the metal is formed of aggregates of primary particles with an average grain size between 10 and 100 nm. In an advantageous embodiment the aggregates have an average grain size between 1 and 20 µm, preferably between 10 and 20 µm. They can have a porosity of 70% to 95%. These features help ensure a uniform and cytotoxically safe release of silver ions at the surface of the material (see the whole of D1). D1 does not disclose a body care product for application to skin and/or mucous membranes.

Document D2 discloses an antimicrobial mixture containing particles of a core material formed from a metal oxide, a sulphate, a sulphide, a zeolite, mica, talc, kaolin, silica or mullite (see D2, column 1, lines 12 to 26; column 2, lines 33 to 55; column 3, line 60 to column 4, line 16; column 5, lines 2 to 55; column 10, line 39 to column 11, line 27; also examples 1 to 11). D2 does not disclose a body care product containing metallic silver for application to skin and/or mucous membranes.

Document D3 discloses a body care product containing metallic silver particles with an average diameter between 1 and 10 μ m (see D3, column 2, line 57 to column 3, line 65; also claims 1 to 13). The metallic particles in D3 are not porous.

International application No.
PCT/EP2004/009536

Box No. V Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement

Document D4 discloses a body care product containing metallic silver particles with an average diameter between 1 and 15 μ m (see D4, column 1, lines 23 to 36; column 2, lines 38 to 46; column 3, lines 6 to 54; column 4, lines 1 to 40; also claims 1 to 7). The metallic particles in D4 are not porous.

3. <u>Inventive step (PCT Article 33(3))</u>

Claims 1 to 31 cannot be considered inventive (PCT Article 33(1) and (3)).

The problem addressed by the present invention is that of providing an antimicrobial body care product that does not have the drawbacks associated with silver nanoparticles.

The problem is solved by the claimed body care product for application to skin and/or mucous membranes, which contains porous metallic particles that contain metallic silver and have an average diameter between 1 and 100 μm .

Document D3, which is considered to be the closest prior art, describes a body care product containing metallic silver particles with an average diameter between 1 and 10 μ m (see D3, column 2, line 57 to column 3, line 65; also claims 1 to 13).

The difference between D3 and the present invention is essentially the fact that the metallic particles are porous.

INTERNATIONAL PRELIMINARY REPORT ON PATENTABILITY

International application No.
PCT/EP2004/009536

Box No. V Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement

This feature is just one of a number of obvious possibilities from which a person skilled in the art would choose according to the circumstances in order to solve the problem of interest, without making an inventive contribution. The subject matter of claims 1 to 31 therefore does not involve an inventive step and thus fails to meet the requirement of PCT Article 33(1) and (3).

4. Industrial applicability (PCT Article 33(4))

The subject matter of claims 1 to 31 is industrially applicable (PCT Article 33(4)).